Hims & Hers Health, Inc. (NYSE:HIMS) is Blueshift Asset Management LLC’s 4th Largest Position

Blueshift Asset Management LLC lessened its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 37.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 154,091 shares of the company’s stock after selling 90,922 shares during the period. Hims & Hers Health accounts for approximately 1.4% of Blueshift Asset Management LLC’s investment portfolio, making the stock its 4th largest holding. Blueshift Asset Management LLC owned about 0.07% of Hims & Hers Health worth $3,726,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. SlateStone Wealth LLC grew its stake in Hims & Hers Health by 4.0% during the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after buying an additional 413 shares during the last quarter. Blume Capital Management Inc. grew its stake in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 600 shares during the last quarter. Quest Partners LLC increased its holdings in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after acquiring an additional 807 shares in the last quarter. Harbour Investments Inc. increased its holdings in shares of Hims & Hers Health by 18.8% during the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock valued at $127,000 after acquiring an additional 833 shares in the last quarter. Finally, Stonekeep Investments LLC raised its position in shares of Hims & Hers Health by 5.5% in the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after purchasing an additional 882 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Performance

HIMS opened at $33.85 on Thursday. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98. The company has a fifty day moving average of $38.88 and a two-hundred day moving average of $28.52. The stock has a market capitalization of $7.52 billion, a price-to-earnings ratio of 76.94 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

HIMS has been the topic of a number of recent analyst reports. TD Cowen restated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Needham & Company LLC upped their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Citigroup reaffirmed a “sell” rating and set a $27.00 price target on shares of Hims & Hers Health in a research report on Thursday, March 6th. Bank of America increased their price objective on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a report on Tuesday. Finally, Leerink Partners upped their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $37.31.

Insider Transactions at Hims & Hers Health

In related news, insider Michael Chi sold 7,259 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $24.07, for a total transaction of $174,724.13. Following the completion of the transaction, the insider now owns 193,601 shares in the company, valued at $4,659,976.07. This represents a 3.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Soleil Boughton sold 4,152 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the transaction, the insider now directly owns 157,345 shares in the company, valued at $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,034,506 shares of company stock valued at $36,635,024 in the last three months. 17.71% of the stock is currently owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.